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Abstract
Background: The purpose of the present study was to check the validity of data collected in BIOREG, the Austrian
register for biological treatment in rheumatology, and to elucidate eventual differences with respect to disease
activity (DA) in patients with rheumatoid arthritis (RA) on established biological DMARDs (bDMARDs) before
inclusion into the register (EST) and beginners at the time point of inclusion (NEW) after 1 year of treatment.
Methods: RA patients with a complete follow-up of 1 year in BIOREG were divided into EST and NEW and
compared with respect to DA, remission rates, concomitant synthetic DMARDs (csDMARDs) and glucocorticoid
therapy (GC) at baseline and after 1-year follow-up. Safety concerns are listed. Descriptive statistics are applied.
Results: For 346 RA patients (284 EST, 62 NEW) out of 970 RA patients included into BIOREG, a full data set for a 1-
year follow-up was available. No differences in DA were observed after 1 year as expressed by DAS28 or RADAI-5,
and small differences as expressed by remission rates according to DAS28, RADAI-5 or Boolean criteria (namely
approximately 1/2, 1/3 to 1/4 and 1/4 to 1/5 of the patients respectively). Sixty-four adverse events (AEs) were
noted in 56 (20 %) of EST and 20 in 19 (31 %) of NEW patients. Malignancy occurred in four patients. After 1 year,
48 % of EST patients but only 16 % of NEW patients were on bDMARD monotherapy.
Conclusion: Regarding DA, the date collected in BIOREG appeared to be valid. After 1 year of bDMARD therapy, all
patients, whether EST or NEW, achieved a similar level of DA. AEs occurred more frequently during the early phase
of bDMARD treatment. Austrian rheumatologists initiate bDMARD therapy in patients with lower disease levels than
in other European countries, leading to high remission rates.
Background
BIOREG, the Austrian register for patients with chronic
rheumatic diseases treated with biological agents, was
established in 2010 [1]. Up to the time of the data report
in October 2015, 970 patients suffering from rheumatoid
arthritis (RA), 276 from psoriatic arthritis, 407 from
spondylarthritis and 51 from other chronic rheumatic dis-
eases such as systemic lupus erythematodes, juvenile arth-
ritis, chronic inflammatory bowel disease and Still disease
were included into the registry. The primary goal of the
register is to document safety concerns, as well as disease
activity (DA) and changes of therapy, and to collect socio-
economic data. Twenty Austrian centres currently take
part in BIOREG (eight rheumatologists in private offices
and 12 specialized rheumatology outpatient clinics in pub-
lic or private hospitals in all nine federal states of Austria).
BIOREG is a member of the European Network of Cen-
tres for Pharmacoepidemiology and Pharmacovigilance
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(ENEPP), is in close partnership with the Austrian Society
for Rheumatology and Rehabilitation (ÖGR) and is sup-
ported by an unrestricted industrial grant. Data analysis is
performed annually in September.
The intention of this study was to check the validity of
the collected data, as well as to get insights into the
“real-world” use of bDMARDs (biologic Disease Modify-
ing Antirheumatic Drugs) in Austria. Therefore, we
compared patients included into BIOREG when starting
bDMARD therapy (NEW) with those on established
bDMARD therapy (EST) at the time point of inclusion.
Disease activity in general, remission rates, concomitant
conventional synthetic DMARDs (csDMARDs), con-
comitant glucocorticoid therapy (GC) and adverse
events were analysed at the time point of inclusion after
1 year. We hypothesized that, emanating from difference
at inclusion, DA should be comparable in EST and
NEW after 1 year of inclusion in BIOREG. Furthermore,
for plausibility, we compared our results with other reg-
isters, e.g. the German register RABBIT [2].
Methods
To be included into this evaluation, it was a prerequisite
that a full data set be available for the respective patients
at the time point of inclusion and after 1 year of obser-
vation. We defined NEW patients as starting on a
bDMARD at the time point of registration in BIOREG
(+/- 30 days); all other patients were regarded as EST
patients.
In all patients, the number of tender and swollen
joints (TJ, SJ) based on the 28-joint count, the erythro-
cyte sedimentation rate in the first hour (ESR) and the
patient’s global assessment of the disease on a 100 mm
visual analogue scale (VASGH), as well as the physician’s
global assessment of disease activity on a 100 mm visual
analogue scale (VASPH), were available. The DAS28-
ESR was calculated [3], and additionally patient-related
outcomes, such as the RADAI-5 [4] and the health as-
sessment questionnaire disability index (HAQ-DI), were
documented [5].
With respect to efficacy, remission rates according to
the DAS28-ESR [6], the Boolean criteria (BC) on the basis
of the 2011 ACR/EULAR remission criteria [7] and remis-
sion as defined by the RADAI-5 disease activity categories
[8] after 1 year were compared. In addition, concomitant
therapies with csDMARDs as well as GC were evaluated,
along with the percentage of patients receiving biological
mono-therapy. With respect to tolerability, adverse events
(AEs) and co-morbidities during the 1-year treatment
period with bDMARDs were compared in both groups,
analysed in relation to all patients with missing data. Pri-
marily descriptive statistics were applied. Where appropri-
ate, median values and the 25th to 75th interquartile
range or percentages were calculated. The deadline for
inclusion into this study was the end of August 2015 (re-
port dated October 2015).
All patients gave their informed consent before inclu-
sion into BIOREG, which is treated as a prospective ob-
servational study. Collection of data is completely
anonymous, using printed case report forms that are
collected in an office for computerizing and analysing
[1]. The central computer is not connected to the World
Wide Web, to avoid data abuse. Data are collected six-
monthly (+/- 3 months). The ethical committee of
Lower Austria has approved the study design of
BIOREG (Reference number GS4-EK-085-2009).
Results
The records of 346 patients complied with the prerequis-
ite of a complete data set, as described, at inclusion and
after 1 year of follow-up (36 % of all in BIOREG included
RA patients, EST N = 284, NEW N = 62).
As shown in the demographic data (Table 1), EST pa-
tients show a 5-year longer median disease duration
than NEW patients; they are on bDMARD therapy for a
median duration of 3.2 years; no age-related differences
are found; rheumatoid factor and/or ACPA are found
positive in 68 % of the EST patients and in 55 % of the
NEW patients; and co-morbidities are recorded in 64 %
of the EST patients and in 73 % of the NEW patients,
respectively. In EST patients, these disorders most
frequently comprise cardiovascular diseases, which ac-
count for 27 %, followed by dyslipidemia in 16 %,
osteoporosis in 14 %, depression in 10 % and diabetes
in 9 %; the respective percentages for NEW patients
are 42, 16, 10, 15 and 10 %. As expected proof of
bDMARD treatment efficacy, EST patients have
milder disease at inclusion than NEW patients, as
expressed by the DAS28 and the RADAI-5 (mild ver-
sus moderate disease activity according to both
scores), as well as by the HAQ-DI.
After 1 year, on the group level, both EST and NEW
patients can be categorized as being in remission accord-
ing to DAS28 and in a mild disease activity stage accord-
ing to the RADAI-5 (Table 2). Accordingly, NEW
patients experienced a good EULAR response [9] and a
significant response according to the RADAI-5 [10].
There was no significant change on either score in EST
patients. Regarding remission as measured by the
DAS28, the RADAI-5 and the BC, after the 1-year obser-
vation period, more than half of the patients were found
in DAS28, approximately 27–36 % in RADAI-5 and 21–
26 % in remission according to the BC, respectively
(Table 3). Additionally, no differences in HAQ-DI-scores
were observed (Table 2).
With respect to concomitant treatment at the time
point of inclusion into BIOREG, a smaller percentage of
patients receiving csDMARDs and GC in the EST group
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were found compared to the NEW patients (Table 3),
as expected. Forty-four percent of the EST patients
took no csDMARDs, while only 16 % of the NEW
patients were on monotherapy with a biological drug.
In EST patients, the most frequently applied
csDMARD was Methotrexate (MTX) in 47 %,
followed by Leflunomide (LEF) in 6 %, Sulphasalazine
(SSZ) in 2 %, and in 2 % combinations of these three
csDMARDs. In the NEW group, the numbers were
63 % MTX, 16 % LEF, 2 % SSZ and 2 % combination,
respectively.
After 1 year of treatment, csDMARD therapy was
stopped in 4 % of the EST patients and in 16 % of the
NEW patients. At the 1-year follow-up visit, 25 patients
(7.2 % of all patients; EST 17 (6 %), NEW 8 (13 %)) had
no concomitant bDMARD considering an accepted
drug-free period of two recommended application inter-
vals. Causes for decanting bDMARDs in EST patients
were remission according DAS28 and/or CDAI and/or
RADAI-5, the patient’s wish and fear of AEs. In the eight
NEW patients, the reasons were intolerance, bDMARD
ineffectivity, the patient’s wish and, in one case, newly
Table 1 Demographics of RA patients included in BIOREG at baseline (if not otherwise indicated, median (25th and 75th percentile))
All pts EST New













Gender % female 77.3 78.4 77.4





































GC % 35.9 25.0 66.1
csDMARD % 64.6 56.0 83.9
Abbreviations: ACPA Anti Citrullinated Peptide Antibodies, bDMARD biological DMARD, csDMARD concomitant conventional synthetic DMARD, DAS28 Disease
Activity Score using ESR out of 28 joints, ESR erythrocyte sedimentation rate, EST pts with established bDMARD treatment before inclusion in BIOREG of whom a
full data set as described is viable, GC concomitant glucocorticoid treatment, HAQ-DI Health Assessment Questionnaire Disability Index, N number of patients, NA
not applicable, NEW pts included in BIOREG with start of biologic treatment ± 30 days of whom a full data set as described is viable, PTS patients, RA rheumatoid
arthritis, RADAI-5 Rheumatoid Arthritis Disease Activity Index-5, RF Rheumatoid Factor
Table 2 Changes of disease activity and HAQ-DI in EST and NEW patients (median (25th and 75th percentile))
EST (n = 284) NEW (n = 62)
baseline after 1 year baseline after 1 year
DAS28 2.67 (1.99, 3.70) 2.58 (1.80, 3.45) 4.46 (3.77, 5.35) 2.43 (1.54, 3.57)
DAS28 Diff 0.18 (-0.47, 0.87) 1.92 (0.65, 2.99)
RADAI-5 2.6 (1.2, 4.4) 2.2 (1.0, 4.0) 4.4 (3.2, 6.2) 2.4 (1.2, 3.8)
RADAI-5 Diff 0.2 (-0.5, 1.2) 2.0 (0.6, 3.4)
HAQ 0.63 (0.13, 1.19) 0.63 (0.13, 1.13) 1.00 (0.63, 1.38) 0.50 (0.13, 1.25)
HAQ Diff 0.00 (-0.13, 0.25) 0.38 (0.00, 0.63)
Abbreviations: DAS28 Disease Activity Score using ESR out of 28 joints, DIFF Difference to baseline after 1 year follow up, ESR Erythrocyte Sedimentation Rate, EST
pts with established bDMARD treatment before inclusion in BIOREG of whom a full data set as described is viable, HAQ-DI Health Assessment Questionnaire
Disability Index, N number of pts, NEW pts included in BIOREG with start of biologic treatment ± 30 days of whom a full data set as described is viable, PTS
patients, RADAI-5 Rheumatoid Arthritis Disease Activity Index-5
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diagnosed prostate cancer. Just 17 of all these patients
were on csDMARD therapy (9 EST, 8 NEW).
With respect to concomitant GCs, considerable differ-
ences between the two groups persisted. Whereas in the
EST group 25 % of the patients were on GCs at inclusion
and 28 % after 1 year, the frequency of GC users in
NEW patients was notably greater, namely 66 % at entry
and 48 % after 1 year.
After 1 year, 64 AEs were observed in 56 EST pa-
tients (20 % of all EST patients) and 20 AEs in 19
NEW patients (31 %) (Table 4); in all available re-
cords after 1 year of observation (n = 511), AEs ap-
peared to occur in a total of 27 % of patients.
Analysis of the recorded AEs of EST and NEW pa-
tients in comparison to all reported AEs in RA pa-
tients after 1 year in BIOREG, showed that infections
in several locations were most frequent in both
groups and comparable to all reported AEs
(approximately 40 %). Mostly upper and lower re-
spiratory tract infections (40 % of reported infections)
occurred, followed by common colds (17 %), urinary
tract infections (12 %), herpetic infections (12 %), en-
capsulated infections such as septic arthritis or ab-
scess (7 %), gastrointestinal infections (7 %) and
others (5 %). Local drug reactions were much more
common in NEW than in EST patients. No opportun-
istic infection was reported.
The proportion of serious adverse events (SAEs) was
higher in EST than in NEW patients, approximately
50 % of all reported AEs in EST and 20 % in NEW pa-
tients, respectively. Fifty-four percent of the SAEs in
EST patients and 25 % in NEW patients were infections;
malignant diseases occurred in four patients (three in
EST patients: relapse of breast cancer, B-cell lymphoma
and thyroid cancer; one in NEW patients: prostate can-
cer). Another two reports of malignant diseases were
Table 3 Percentages of remission at baseline and 1-year follow-up and percentages of concomitant csDMARD and GC therapy in
EST and NEW patients
EST n = 284 NEW n = 62
baseline after 1 year follow up baseline after 1 year follow up
DAS28 remission % 47.2 51.1 1.6 53.2
RADAI-5 remission % 31.3 36.3 1.6 27.4
BC remisson % 21.1 26.1 1.6 21.0
GC% 25.0 27.8 66.1 48.4
csDMARD % 56.0 51.8 83.9 67.7
bDMARD % 100.0 94.0 na 87.1
Abbreviations: BC Boolean criteria, bDMARD biologic DMARD, csDMARD conventional synthetic DMARD, DAS28 Disease Activity Score using ESR out of 28 joints, ESR
Erythrocyte sedimentation rate, EST pts with established bDMARD treatment before inclusion in BIOREG of whom a full data set as described is viable, GC
glucocorticoid; na not applicable, NEW pts included in BIOREG with start of biologic treatment ± 30 days; pts patients, RADAI-5 Rheumatoid Arthritis Disease
Activity Index-5
Table 4 Adverse events during first year of observation (+/- 3 months). Adverse events reported fewer than three times are not
listed, except that there were at least three reported adverse events in one group of patients. (Number of reported cases (in N of
patients), % of all reported adverse events). The last two columns describe adverse events recorded in all patients included in
BIOREG RA-group with completed 1-year observation (n = 511)
EST (in 19.7 % of pts) NEW (in 30.7 % of pts) All RA pts in BIOREG with one year of observation (in 26.8 % of pts)
All 64 (56) 100 % 20 (19) 100 % 153 (137) 100 %
SAE 31 (23) 48.4 % 4 (4) 20.0 % 72 (58) 47.1 %
Infections 25 (23) 39.1 % 8 (8) 40.0 % 60 (56) 39.2 %
Ulcerative skin lesions 4 (4) 6.3 % 1 (1) 5.0 % 6 (6) 3.9 %
Malignant diseases 3 (3) a 4.7 % 1 (1) b 5.0 % 6 (6) c 3.9 %
Ophthalmic diseases 3 (3) 4.7 % 0 7 (7) 4.6 %
Thrombotic diseases 3 (3) 4.7 % 1 (1) 5.0 % 4 (4) 2.6 %
Intolerance of biologic drug 1 (1) 1.6 % 3 (3) 15.0 % 9 (9) 5.9 %
Vertigo 3 (2) 4.7 % 0 3 (2) 2.0 %
Others 22(17) 34.4 % 6 (6) 30.0 % 58 (55) 37.9 %
Abbreviations: EST pts with established bDMARD treatment before inclusion in BIOREG of whom a full data set as described is viable, NEW pts included in BIOREG
with start of biologic treatment ± 30 days of whom a full data set as described is viable, PTS patients, RA rheumatoid arthritis, SAE serious adverse event
a relapse of breast cancer, B-cell lymphoma, thyroid cancer
b prostate cancer
c as listed plus colorectal cancer and lung cancer
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detected in all viable records of RA patients after 1 year
of observation (one case of colorectal cancer and one of
lung cancer). Thus, in summary, neither a higher occur-
rence rate nor organ or tumor specificity of malignancies
was revealed. No fatal casualties were reported.
Discussion
As expected, treatment of RA patients with bDMARDs
proved to be effective in EST and NEW patients. NEW
patients, in whom bDMARD therapy was started in
moderate disease activity, achieved remission or low dis-
ease activity according to the DAS28 and the RADAI-5
after 1 year of observation, while EST patients remained
stable in remission or low disease activity. After 1 year
of observation, both EST and NEW patients achieved
comparable DA, supporting the validity of the BIOREG
data.
Remarkably high percentages of patients in remission
were observed, not only according to the DAS28 (more
than 50 % in both groups) or to the RADAI-5 (approxi-
mately 27 % in EST—and 36 % in NEW patients), but
also according to the BC (26 % of the patients in the
EST group, 21 % in the NEW group). The varying rates
of patients in remission, depending upon the definition
applied, are well known [11]; however, other reports
dealing with remission rates do not show as high rates
as presented here [12, 13]. One plausible reason for this
may be that biological treatment in Austria is initiated in
patients with milder disease than in other countries [14].
Better outcomes in milder than higher diseased patients
are underlined by a recent study conducted in a five-
centre Norwegian register [15], as well as in the German
register RABBIT, which recorded a 30 % DAS28 remis-
sion rate when bDMARD therapy was started in moder-
ate DA [16].
NEW patients’ median disease activity according to
the DAS28 before starting bDMARDs is somewhat lower
in BIOREG compared to other European bDMARD
registries (4.13 compared to 4.2–6.6), while median
HAQ-DI scores are in a comparable range (1.0 vs 0.8–
1.9) [14]. bDMARDs in RA in Austria are restricted to
patients having failed to thrive on at least one
csDMARD (preferably MTX), and only rheumatologists
are licensed for their prescription [17]. Although this
may suggest a more liberal prescription of bDMARDs in
Austria than in other European countries, initiation of
bDMARDs in Austria follows the relevant EULAR rec-
ommendations [18].
Starting bDMARDs in moderately active diseased
patients showed somewhat better numerical outcomes
as measured by different instruments than commen-
cing at a high disease activity level [16, 19]. Regarding
all patients after 12 months since BIOREG inclusion
(n = 511), the median DAS28 was at the upper limit
of remission (2.60 (25th and 75th percentile 1.80;
3.45)) and the median RADAI-5 was in the mild dis-
ease activity range (2.2 (1.0; 3.6)), indicating efficacy
when assessed by a composite index and by a patient-
reported outcome. This result may also be seen as an
indicator that the patients included into this observa-
tion may be representative for all RA patients on the
register.
As expected, in more NEW patients AEs were recog-
nized during their first year of treatment with
bDMARDs than in EST patients. Those AEs were
mostly injection site reactions. Although NEW patients
show higher disease activity, more frequently receive a
higher amount of GC and csDMARDs and have more
concomitant diseases, such as cardiovascular diseases,
compared to EST patients, no more infectious complica-
tions were observed than in the EST group [20]. This
finding may be in part due to the relatively short median
exposure to bDMARDs in the EST group, namely
3 years, compared to an observation in the German
register RABBIT, where 3 years was the cut-off to be
regarded as “new on the drug” [21]. Compared with the
RABBIT register, on which 13 % of the included patients
experienced an infection in the first year of observation
(out of them 6 % received a csDMARD without
bDMARD), a similar overall percentage of infection of
11.7 % in all available AEs reports after 1 year in
BIOREG is reported [22]. However, there remains a dis-
crepancy in the valuation of seriousness: whereas in
BIOREG 53 % of these infections are indicated as serious
in all available AE reports (54 % in EST, 25 % in NEW),
in the RABBIT register this percentage is 26 % [22],
which may be founded on different therapeutic strategies
concerning infections. NEW patients fulfil the criterion
in the RABBIT register, where patients are included at
the start of bDMARD therapy, whereas EST patients in
BIOREG are on bDMARD therapy for a median
3.2 years. Since most reports about this issue conclude
that serious infections are most likely during the first years
of bDMARD therapy and are associated with age,
co-morbidities, concomitant GC use, high-dose
bDMARD, previous treatment with csDMARD and dis-
ability [23–26], further evaluations of this finding seem
necessary to elucidate this discrepancy.
The most striking differences between the EST and NEW
patient groups were related to concomitant treatment. EST
patients took GCs (approximately 25 %) and csDMARDs
(almost 50 %) much less frequently than NEW patients at
the beginning, as well as after 1 year. This also mirrors the
general intention to reduce the amount of medication in
cases of successful treatment with bDMARDs. The overall
use of GCs in the biological era is decreasing, although it is
still high in clinical practice, at about 50 % on average [27].
Compared to more than 70 % GC co-treated patients in
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the German RABBIT register, concomitant GC use in
NEW BIOREG patients was found to be comparable,
namely 66 % at baseline [28]. GCs are an important factor
for co-morbidities in RA patients [29, 30], not only for in-
fections but also for conditions such as osteoporosis, dia-
betes, cardiovascular diseases or skin atrophy. A fortiori,
around 25 % of GC users in the EST patients give hope that
the use of GCs may be reduced in the future and underlines
the effectiveness of bDMARD therapy.
At baseline, 44 % of the EST patients and 16 % of
NEW patients received their bDMARD in monotherapy.
In line with this finding, csDMARD therapy was stopped
during the 1-year observation in 4 % of the EST patients
and in 16 % of the NEW patients. An evaluation of all
RA patients included in BIOREG revealed approximately
40 % of patients receiving bDMARDs as monotherapy at
baseline. The percentage of RA patients on bDMARD
monotherapy seems to increase with time of treatment
[31], underlining the intention of Austrian rheumatolo-
gists to optimize therapy by reducing GCs and
csDMARDs and keeping the patient on the ultimately
effective drug after having achieved the treatment goal.
In the case of treatment success, Austrian rheumatolo-
gists follow the EULAR recommendations for adopting
therapy when the treatment target is reached [18].
bDMARD monotherapy seems not to be exceptional in
Europe, even though lower rates are commonly reported
(19–27 %) [32, 33].
In patients with two or more csDMARD failures, the
addition of a bDMARD doubles the chance of achieving re-
mission compared with switching to a csDMARD [16]. In
the report from the RABBIT register, high remission rates
(DAS28 remission: 30.6 %; ARA remission: 16.9 %) were
observed in bDMARD patients with moderate disease ac-
tivity according to the DAS28 at the start of treatment.
These rates decreased to 8.5 % in patients with DAS28 > 6
at the time point of starting bDMARD [16]. These findings
underline those derived from BIOREG. Not adding a
csDMARD as a double- or triple-therapy, which has also
been shown to be clinically effective [34, 35] with no differ-
ence in loss of work [36] but higher drop-out rates in the
combination csDMARD groups, is an expensive approach
[37]. In BIOREG, only 2 % of EST and NEW patients were
on a combination of csDMARDs when starting the
bDMARD. A 1-year course of therapy with a bDMARD in
Austria costs €14,300– €20,000, depending upon the drug
and the dosage and administration [38]. Austria may be
classed among countries with a liberal prescription policy
[39]. However, a Treat to Target principle, with consecutive
bDMARD after two csDMARD failures, seems to be cost
effective after 2 years of treatment [40]. In addition, it
should be considered that patients in BIOREG were treated
for a median 6 years in EST and 4 years in NEW patients
with several csDMARDs. Since bDMARDs are expensive
and carry risks of adverse events, trials have been con-
ducted with stopping TNFα-blockers [41] or tapering them
down when remission or stable low disease activity has
been achieved [42]. Decanting TNFα-blockers shows worse
clinical outcome than continuing, whereas cautious dose
reduction at least for Etanercept or Adalimumab could be
regarded a valuable alternative.
This study has limitations, the most important being the
small number of NEW patients, as a result of the intention
to include only patients with a full dataset available for a
longitudinal study on tolerability and disease activity and
therefore to avoid missing data [43]. Since BIOREG in-
cludes patients irrespective of the date of their initiation
on bDMARDs, this disparity is an unavoidable drawback.
Therefore, the presented data may give insights into the
use of bDMARDs in Austria, but the section referring to
the seriousness of AEs in particular has to be regarded
with caution.
Conclusion
In summary, this first evaluation of data extracted from
BIOREG, the register for bDMARDs in Austria, indicates
successful RA treatment with bDMARDs in Austria at rea-
sonable tolerability. Validity of the data could be evidenced
by showing NEW patients at comparable disease activity as
EST patients after 1 year of bDMARD therapy. Plausibility
is indicated by comparison of the results with the RABBIT
register, with one exception, namely the high rate of serious
AEs in the form of infections in EST patients. Starting
bDMARD at lower disease activity than in other European
countries is possibly accompanied by higher remission
rates, not only expressed by DAS28 or BC but also indi-
cated by a patient-reported outcome, the RADAI-5, and
higher rates of bDMARD monotherapy. This fact may
imply more cost-intensive treatment while suggesting the
possibility of better outcomes for patients. Additionally,
after having achieved the treatment goal, it appears to be
general practice in Austria to primarily reduce or even
stop treatment with csDMARDs and GCs, while keeping
patients on bDMARDs to maintain the therapeutic
success.
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